Photo taken from Allison Betof Warner/X
Jun 2, 2024, 09:37
Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24
Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford Cancer Institute, recently posted on X:
“We’ve been waiting for this one!!
RELATIVITY-048 (ipilimumab 1Q8wi and nivolumab and relatimab) presented by Paolo A. Ascierto.
ORR 52% by BICR. Clinical benefit rate 76%. 50% discontinuation due to toxicity.
Responses in poor prognosis disease.
7/14 with liver metastasis and 2/3 with brain metastasis responded. More to come on brian mets with this combination!
Rate of G3/4 TRAE is a 39%…actually significantly better than full dose ipilimumab and nivolumab.”
Source: Allison Betof Warner/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 6, 2025, 17:46
Apr 6, 2025, 17:36